酸素化コレステロール硫酸塩（ＯＣＳ）の使用

Japanese Patent JP7009059

B2

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

JP2021176832	MIFEPRISTONE ORAL DOSAGE FORM FOR USE IN CERVIX RIPENING AND LABOR PAIN INDUCTION
JPH11246414	STEROID 5-ALPHA-REDUCTASE II-TYPE-SPECIFIC INHIBITOR
JP5581265	Use of the lipid conjugate in the medical treatment of a disease

Ren, Shun Lin
Thewwes, Felix
Brown, James, Yi.
Lynn, Wei Chi

JP2016542662A

February 10, 2022

December 23, 2014

Click for automatic bibliography generation  

Virginia Commonwealth University
Direct Corporation

A61K31/575; A61P13/12

WO2013154752A1
US20120264816

Am.J.Physiol.Renal.Physiol.,2008,294(5),p.F1032-1047
Am.J.Physiol.Endocrinol.Metab.,2012,302,p.E788-E799(URL,doi:10.1152/ajpendo.000337.2011)
Nephrol.Dial.Transplant.,2012,27,p.174-181(URL,doi:10.1093/ndt/gfr240)
Kidney International,2007,71,p.1232-1239
Journal of Surgical Research,2012,182,p.176-184(URL,http://dx.doi.org/10.1016/j.jss.2012.08.020)
American Journal of Nephrology,2003,23,p.267-276(URL,DOI:10.1159/000072088)
Kidney Int.2005,68,sup99,p587-593
Clin.J.Am.Soc.Nephrol.,2011,6,2567-2572
J.Am.Coll.Cardiol.,2008、51(15),p.1448-1454

Yusuke Hiraki
Setsu Fujita
Natsuo Tanaka

Previous Patent: Optical scanning device and image forming device equipped with it

Next Patent: Equipment and methods for implementing predictive system error correction in location-specific proce...